Product Name | Eltrombopag | Eltrombopag Free Base |
---|---|
CAS | 496775-61-2 |
Formula | C25H22N4O4 |
MW | 442.47 |
Appearance | Yellow to orange powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
10 mg | In-stock | $138.00 | Visible after login | |
25 mg | In-stock | $220.00 | Visible after login | |
50 mg | In-stock | $352.00 | Visible after login |
Product Name | Eltrombopag | Eltrombopag Free Base |
---|---|
CAS | 496775-61-2 |
Formula | C25H22N4O4 |
MW | 442.47 |
Appearance | Yellow to orange powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Eltrombopag (formerly SB-497115; SB 497115; SB497115; trade name PROMACTA), a member of the biarylhydrazone class, is a novel nonpeptide agonist of the thrombopoietin receptor (TpoR) approved for use in the treatment of chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP). Eltrombopag demonstrates an EC50 of 0.27 μM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR. Eltrombopag activates the receptor by association with metal ions (i.e., Zn2+) and specific amino acids within the transmembrane and juxtamembrane domains of the TpoR.